clairop

Does Mesalamine Work for Ulcerative Colitis?

Yes for most mild to moderate ulcerative colitis. What the Cochrane and guideline numbers show, how long it takes, oral vs rectal, and how to judge response.

Clairop Team19 min read

Photo: TA NI / Unsplash

The short answer

Mesalamine (5-ASA) works for many people with mild to moderate ulcerative colitis, but not for everyone. In Cochrane trials about 29% reached clinical remission on it versus 17% on placebo, and it roughly cut relapse from 55% to 37% over a year. Rectal forms, missed doses and disease severity change the odds. Judge response with your gastroenterologist.

Trying to find your triggers? Clairop logs meals, symptoms and stool in seconds on iPhone, then flags foods your gut reacts to, including delayed reactions.

Get it on the App Store

Mesalamine (also called mesalamine or 5-ASA, an aminosalicylate anti-inflammatory taken as tablets, granules, suppositories or enemas) works for many people with mild to moderate ulcerative colitis, and it is the standard first-line medicine for that group. It is not a guarantee: in trials a large share of people still do not reach remission on it, and it is much less likely to control severe disease. This guide shows the actual numbers, what changes the odds, and how to judge your own response alongside your gastroenterologist.

It is information, not advice about your treatment. We do not tell anyone to start, stop, switch or change the dose of any medicine, and nothing here replaces your prescriber. It is written from a US point of view first, with UK and Europe notes where guidelines differ in wording only (mesalamine is the UK and European spelling).

Does mesalamine work for ulcerative colitis?

Yes, for a substantial share of people with mild to moderate disease, with the strongest evidence for inducing and keeping remission. The Cochrane review of 54 trials (9,612 participants) found that 5-ASA beat placebo with high-certainty evidence (Murray 2020, induction). The honest framing is "works for many, enough for some, not enough for others".

Here is what that review actually measured. Seventy-one percent of people given 5-ASA failed to reach clinical remission, compared with 83% of people given placebo (relative risk 0.86; 11 studies, 2,387 participants). Turned around, about 29% reached remission on 5-ASA and 17% on placebo, which is a meaningful difference but far from universal. The review also found that side effects were no more common on 5-ASA than on placebo, and that there was no clear difference in remission between 5-ASA and the older drug sulfasalazine, though sulfasalazine was less well tolerated (Murray 2020, induction).

Two caveats shape how to read those numbers. First, trial remission is usually a strict, composite definition, so the share who feel clearly better is typically higher than the share who meet it. Second, the pooled trials mix people with different disease extent and activity. A single person's odds depend on where their colitis is and how active it is, which is the next question.

How well does mesalamine work, and for whom?

It works best for mild to moderate disease and for inflammation that the medicine can reach. Guidelines position 5-ASA as first-line for mildly to moderately active ulcerative colitis, and they state plainly that disease not responding to it moves into the same toolbox used for more active disease (Guideline Central summary of the ACG guideline).

SituationWhat guidelines and trials say
Mild to moderate, extensive or left-sided colitisThe AGA recommends standard-dose oral mesalamine or diazo-bonded 5-ASA over low-dose mesalamine, sulfasalazine or no treatment, and suggests adding rectal mesalamine (Ko 2019)
Proctitis or proctosigmoiditis (lower bowel only)The AGA suggests enemas or suppositories rather than oral mesalamine, and recommends suppositories for proctitis (Ko 2019)
Moderate activity or a suboptimal responseThe AGA suggests a higher dose together with rectal mesalamine (Ko 2019)
Mild disease with high-risk featuresThe ACG key concepts say people with prognostic factors for hospitalization or surgery should be treated with moderate to severe disease therapies (Guideline Central summary of the ACG guideline)
Severe diseaseNot a 5-ASA problem; see your doctor promptly (details below)

If you are unsure what your extent is, ask which part of the colon is involved. The word on your report (proctitis, left-sided, extensive) steers which form is sensible. Our guide to ulcerative proctitis vs ulcerative colitis explains the extent categories.

In r/UlcerativeColitis, the most common pattern in threads asking whether mesalamine "actually works" is that people with mild disease and long-term users describe years or decades of remission, while people whose colitis became more active often say it helped when disease was mild and not once it was not (one thread). That matches the trial picture. It is lived experience, not evidence, but it lines up with what the data predict.

How long does mesalamine take to work for ulcerative colitis?

Weeks, not days, for the full effect. In two pooled 6-week trials, endoscopic improvement (an endoscopy subscore of 0 or 1) was reached by 58% of people with moderately active disease on the standard-dose arm at week 3 and 68% at week 6; the higher-dose arm reached 65% and 80% (Lichtenstein 2011). The ACG key concepts suggest reassessing response to induction therapy within 8 weeks (Guideline Central summary of the ACG guideline).

Two things follow. Healing keeps improving between week 3 and week 6, so judging at two weeks can be premature. And the 8-week mark is a decision point: if the picture is not clearly better by then, guidelines expect a review, not more waiting.

Some people in r/UlcerativeColitis describe feeling dramatically better within days, often alongside a short steroid course, while others describe a slower, steadier improvement (a second thread). Both are within the range the trials allow. If a steroid was started at the same time, it is hard to tell which medicine produced the quick change, which is one reason clinicians check objective markers and not only how you feel.

How long a flare lasts without effective treatment is covered in how long does a UC flare last.

Is rectal mesalamine better than oral, or should you take both?

It depends on the location of the disease, and for many people the combination performs best. A meta-analysis of four trials found combined oral and rectal 5-ASA beat oral 5-ASA alone for inducing remission (relative risk of no remission 0.65, number needed to treat 5), while topical alone was not clearly different from oral alone (relative risk 0.82, 95% CI 0.52 to 1.28) (Ford 2012).

The network meta-analysis of 75 trials (12,215 patients) ranked combined oral and rectal 5-ASA first for induction. Failure to induce remission was lower than with standard-dose oral mesalamine (odds ratio 0.41, 95% CI 0.22 to 0.77), and high-dose oral mesalamine was also better than standard dose (odds ratio 0.78, 95% CI 0.66 to 0.93). For maintenance, neither the combination nor the high-dose option was better than standard-dose mesalamine (Nguyen 2018).

RouteBest evidenceWhere it fits
Oral (tablets, granules)Beats placebo for remission and relapse prevention (Murray 2020, induction)Disease reaching higher in the colon
Rectal (suppository, enema, foam)Beats placebo for symptomatic, endoscopic and histologic remission in distal disease, and beats rectal steroids (Marshall 2010)Proctitis, proctosigmoiditis, left-sided disease
Oral plus rectalSuperior to oral alone for induction (Ford 2012)Left-sided or extensive disease when the doctor judges it appropriate

For maintenance, the rectal evidence is smaller but encouraging: in a Cochrane review of nine studies, 62% of people on rectal 5-ASA kept symptomatic remission over 12 months versus 30% on placebo, though the certainty was rated low because the data were sparse and inconsistent (Marshall 2012). A separate meta-analysis found intermittent topical 5-ASA seemed to prevent relapse better than oral alone in quiescent disease (relative risk 0.64, number needed to treat 4) (Ford 2012).

People in r/UlcerativeColitis talk about rectal products with a mix of praise and reluctance. Some say they work because they deliver medicine to the sigmoid and rectum where the inflammation is, and others say they simply cannot face them (thread). That reluctance is worth saying out loud to your doctor, because a treatment that is not used cannot work. Whether to add or change any form is your prescriber's decision.

Does mesalamine keep ulcerative colitis in remission?

For many people, yes. In the Cochrane review of oral 5-ASA for maintenance (44 studies, 9,967 participants), 37% of people on 5-ASA relapsed at 6 to 12 months compared with 55% on placebo (relative risk 0.68, high-certainty evidence) (Murray 2020, maintenance).

That is a large effect, and it is also a reminder of what remission on mesalamine is: a lowered chance of relapse, not a switch that stays off. About one in three people on 5-ASA still relapsed within a year in the trials. The review also noted that sulfasalazine was slightly more effective for maintenance than 5-ASA (48% versus 43% relapsing) but is generally less well tolerated (Murray 2020, maintenance).

Guidelines are consistent that maintenance should use therapy with proven benefit in preventing relapse, and the ACG recommends against systemic steroids, budesonide MMX or topical steroids for maintenance (Guideline Central summary of the ACG guideline). Whether you can ever come off treatment is a separate question, covered in can you live without medication with ulcerative colitis. Please do not use the numbers above as a reason to adjust anything yourself.

Does the brand, dose or number of daily doses change the answer?

Less than most people expect. The Cochrane review found no clear difference in efficacy between 5-ASA formulations in active disease (50% versus 52% failing to enter remission, relative risk 0.94) and no difference in remission between once-daily and conventional dosing (60% versus 61% failing, relative risk 0.99, high-certainty evidence) (Murray 2020, induction).

The same holds for staying well. Once-daily and conventional dosing relapsed at 37% and 39% over 12 months (relative risk 0.94, high-certainty evidence) (Murray 2020, maintenance). That is why the ACG says either once-daily or more frequent dosing can be used based on patient preference to optimize adherence (Guideline Central summary of the ACG guideline), and the AGA suggests once-daily dosing for people on oral mesalamine (Ko 2019).

Dose is a different question. In the ASCEND II trial of people with moderately active disease, 72% of those on the higher-dose arm had treatment success at week 6 versus 59% on the standard arm (Hanauer 2005), which is why guidelines mention higher doses for moderate activity or suboptimal response. These are reference points from trials, not an instruction. Your prescriber chooses dose and form. If a properly dosed course did not work, the ACG suggests against swapping to another 5-ASA formulation and says to consider other therapeutic classes (Guideline Central summary of the ACG guideline). What comes after is the subject of what to take when mesalamine stops working, which we kept separate on purpose: this page is about whether and how well it works, that one is about the ladder that follows.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Why do some people say mesalamine did nothing?

Usually because of severity, extent, adherence or a look-alike problem, not because the drug is inert. The trial data already show that a majority of people in induction trials did not reach remission on 5-ASA alone, so "it did nothing for me" describes a very common outcome (Murray 2020, induction).

Reasons to discuss with your gastroenterologist, none of which you should act on alone:

  • Disease more active than 5-ASA can handle. It helped in mild disease and not once colitis became severe is a recurring theme in r/UlcerativeColitis (thread), and it fits guidelines.
  • Wrong location for the form used. Granules or tablets may not reach a rectum-heavy problem the way a suppository does, which several people describe (thread).
  • Missed doses. Covered in the next section.
  • Infection or another cause. A flare after antibiotics or a stomach bug can mimic drug failure and needs a stool test.
  • Not colitis symptoms at all. IBS-type symptoms can coexist with quiet inflammation, which is why doctors check calprotectin or look with a scope.
  • Rarely, the drug itself. The US label describes an acute intolerance syndrome, seen in about 3% of patients in controlled trials, whose cramping, abdominal pain and bloody diarrhea may be hard to tell apart from a flare (DailyMed Lialda label). Tell your prescriber or pharmacist promptly if symptoms worsen soon after starting or changing a product.

One more honest caveat: some people in these threads describe symptoms fading quickly after a short steroid course given with mesalamine, then returning when the dose changed or after an infection. A flare after any medicine change or illness is a conversation with your doctor, not proof of what caused it.

How much do missed doses change the odds?

A lot, and this is the most fixable reason for apparent failure. In a prospective cohort of 99 people in remission on maintenance mesalamine, all 12 relapses at 6 months were in people who refilled less than 80% of their supply, and over a year nonadherent people had more than five times the relapse risk (hazard ratio 5.5, 95% CI 2.3 to 13) (Kane 2003).

Adherence in real life is imperfect. In an earlier study of 94 outpatients with quiescent disease, only 40% took at least 80% of their dispensed supply, and the median amount taken was 71% of what was prescribed (Kane 2001). Taking more than four prescription medicines and being male were associated with nonadherence.

A small randomized trial of once-daily versus conventional dosing (20 patients) found no significant difference between regimens, but adherence itself was strongly linked to staying well: none of the adherent once-daily patients flared versus 6 of 7 nonadherent ones (Kane 2008). It was small and preliminary, so treat it as a pointer. These are all older studies, but they agree with guideline advice to choose dosing around what you will actually take.

Skipped doses are rarely a character flaw. Enemas are unpleasant, big tablets are annoying and remission makes pills feel pointless. If that is you, tell your doctor or pharmacist, because a simpler plan is one of the few levers that cost nothing. How cost can get in the way is covered in how to afford ulcerative colitis medication.

How can you tell if mesalamine is working?

Track the same few things every day and compare them with objective tests your doctor orders. The treatment targets set by an international consensus include symptom relief, normal calprotectin and CRP in the short term, and clinical remission with endoscopic healing in the long term (STRIDE-II, Turner 2021). Symptoms alone are only part of it.

The two symptoms trials rely on are stool frequency and rectal bleeding, combined as the PRO-2 score. The researchers who developed it derived it from the data of a mesalamine induction trial, and called it an interim measure for trials (Jairath 2015). Our explainer on the PRO-2 score covers how it is scored and what it misses (urgency, pain and fatigue).

What to logWhy it helps your doctor
Number of stools per dayMaps to the frequency item in PRO-2
Blood present or notMaps to the bleeding item in PRO-2; our guide to how much blood is normal explains what to report
Urgency, tenesmus, accidentsWhat PRO-2 leaves out and what bothers people most
Night-time bowel movementsA sign of more active disease that doctors ask about
Every missed dose and every dose changeSeparates "drug failed" from "drug not taken"
Illness, antibiotics, NSAID use, big stressorsCommon reasons for a short-lived dip
Test dates and results (calprotectin, CRP, kidney function)Lets you see symptoms and markers side by side

Objective checks matter because symptoms and inflammation do not always match. The AGA biomarker guideline suggests that in people whose symptoms are quiet, a fecal calprotectin under 150 micrograms per gram can help rule out active inflammation, and that people with mild symptoms should have endoscopic assessment to guide treatment (Singh 2023). Our guide to what calprotectin levels mean in ulcerative colitis explains the numbers, and signs ulcerative colitis is healing covers the in-between stage.

If you use Clairop, its one-page report puts stool pattern, blood, overnight episodes, missed doses and test results in one view for an appointment; you can see how it works on the how it works page. A paper log does the same job. It is patient-entered, it does not interpret anything and it cannot tell you what to take.

What do you need to monitor while on mesalamine?

Kidney function is the main one, and your prescriber sets the schedule. The US label says to assess kidney function at the start of treatment and periodically during treatment, and notes that renal problems including interstitial nephritis and, rarely, renal failure have been reported with mesalamine products (DailyMed Lialda label).

A systematic review of 41 case reports of biopsy-proven 5-ASA kidney inflammation in people with IBD found mesalamine accounted for 95% of them, the median time to diagnosis was 2.3 years, and 15% developed end-stage renal failure; the authors suggested monitoring kidneys at least every six months (Moss 2022). Case reports cannot tell you how rare this is, so it should not make anyone fearful. It is the reason to keep blood-test appointments even during years of feeling well, and to tell your prescriber about swelling, reduced urine or new unexplained symptoms.

Everyday side effects reported in the Cochrane trials were mostly mild: flatulence, abdominal pain, nausea, diarrhea and headache, and they were no more common than with placebo (Murray 2020, induction).

When should you see a doctor promptly?

Do not wait for the next routine visit if you have any of the following. Heavy or increasing blood in the stool, fever, severe abdominal pain, signs of dehydration or vomiting that stops you keeping fluids down need urgent medical care. Our guide on when to go to the hospital for a UC flare lists these in detail.

Also contact your gastroenterologist promptly for any of these: symptoms that are worsening or not clearly better after the first weeks of a new regimen, a flare after antibiotics or a stomach bug, new swelling or reduced urine, chest pain or breathlessness after starting a mesalamine product, or unexplained weight loss. Telling your doctor early is not an overreaction; it is how a plan that is not working gets reviewed in time.

What do people get wrong about mesalamine?

Most mesalamine myths come from mixing up "first-line" with "weak" and "did not work for me" with "does not work". Six come up repeatedly, and each has a sourced answer.

  • "It is just a mild drug, so it cannot really do anything." The trial evidence shows a clear effect on remission and relapse, with high-certainty ratings (Murray 2020, maintenance).
  • "If it did not work, I am a failure." About seven in ten people in induction trials did not reach remission on 5-ASA alone (Murray 2020, induction). It says something about disease severity, not about you.
  • "A more expensive brand will work better." The Cochrane review found no clear difference between formulations (Murray 2020, induction).
  • "If I feel fine, I can skip it." Nonadherence was strongly linked to relapse in the cohort data (Kane 2003). Any change to your plan belongs to your prescriber.
  • "Rectal treatment is a last resort." For distal disease, rectal 5-ASA is a first-line option, not an escalation (Marshall 2010).
  • "Mesalamine failing means I need a biologic." Possibly, but guidelines first confirm active inflammation and rule out missed doses and infection. See are biologics worth it for ulcerative colitis for that decision, made with your doctor.

What should you ask your gastroenterologist about mesalamine?

The most useful questions are about extent, what counts as response, when it will be reassessed and which tests will be used. The ACG and AGA both frame treatment as a shared decision, so all of these are fair game (Guideline Central summary of the ACG guideline).

  1. How far does my colitis extend, and is the form I am using the right one for that location?
  2. What will count as "working" for me, and when will we reassess (the ACG suggests within 8 weeks for induction)?
  3. Which objective tests will we use, such as calprotectin, CRP or a scope?
  4. How often do you want kidney function checked while I take it?
  5. Is there anything about my routine that makes doses easy to miss, and can the plan be simpler?
  6. Which symptoms should make me call you before the next visit?
  7. If it is not enough, how would we decide what comes next?

Our checklist for how to prepare for a GI doctor appointment helps you bring the right information. If a flare comes back after a stretch of remission, how do I know if my ulcerative colitis is flaring explains what to look for.

The bottom line

Mesalamine works for many people with mild to moderate ulcerative colitis, with high-certainty evidence for both inducing remission and preventing relapse, and it is well tolerated overall. It is not enough for everyone, it works best when the form matches where the inflammation is, and missed doses can mimic failure. The best way to find out whether it is working for you is a daily log plus objective tests reviewed with your gastroenterologist.

If your response is falling short, that is information for the next conversation, not a verdict on you. Never start, stop or change a medicine on the strength of a web article, including this one.

Frequently asked questions

Does mesalamine work for ulcerative colitis?
For many people with mild to moderate disease, yes. A Cochrane review of 54 trials found 29% reached clinical remission on 5-ASA versus 17% on placebo, with high-certainty evidence. It works less often in severe disease and does not work for everyone. Your gastroenterologist judges response with symptoms and objective tests.
How long does it take mesalamine to work for ulcerative colitis?
Trial data suggest weeks, not days. In two pooled 6-week trials, endoscopic improvement was reached by 58% to 65% of people with moderate disease at week 3 and by 68% to 80% at week 6. The ACG suggests reassessing response to induction therapy within 8 weeks. Some people feel better sooner, some later.
Is rectal mesalamine better than oral mesalamine?
It depends on where the inflammation sits. For disease limited to the rectum or lower colon, the AGA suggests enemas or suppositories over oral tablets. Combining oral and rectal 5-ASA beat oral alone for inducing remission in a meta-analysis (relative risk of no remission 0.65). Your doctor picks the form.
Can mesalamine keep ulcerative colitis in remission?
For many people, yes. In a Cochrane review of maintenance trials, 37% of people on 5-ASA relapsed within 6 to 12 months compared with 55% on placebo (high-certainty evidence). Remission is not guaranteed, and missed doses matter: in one cohort, people who refilled less than 80% of their supply had about five times the relapse risk.
Why is mesalamine not working for me?
Common reasons are disease that is more severe or extensive than 5-ASA can control, missed doses, infection, a look-alike condition such as IBS-type symptoms, or, rarely, intolerance to the drug itself. Guidelines say to confirm active inflammation first. Bring a log of stools, blood and missed doses to your gastroenterologist rather than changing anything yourself.
Does the brand of mesalamine matter?
Evidence says less than people expect. A Cochrane review found no clear efficacy difference between 5-ASA formulations in active disease (50% versus 52% failing to reach remission). The ACG suggests against switching to another 5-ASA formulation if a properly dosed course did not work. Cost, tolerability and delivery site still matter, so discuss it with your prescriber.
Do I need blood tests while taking mesalamine?
Usually yes. The US label for one mesalamine tablet says to assess kidney function at the start and periodically during treatment because kidney problems, including interstitial nephritis, have been reported. How often is your prescriber's decision. Case reports suggest problems can appear after years of use, so keep the appointments even when you feel well.
Is mesalamine safe long term?
It is generally well tolerated: in Cochrane trials, side effects were no more common than on placebo. Rare serious effects include kidney inflammation and an acute intolerance syndrome that can mimic a flare. Long-term use is why guidelines pair it with periodic kidney checks. Tell your prescriber about new symptoms rather than stopping it yourself.
What is the best way to track whether mesalamine is working?
Log stool count per day, whether there was blood, urgency, night-time bowel movements and every missed dose or dose change. Those items map onto PRO-2, the stool frequency and rectal bleeding score used in trials. A paper log works. Clairop is one iPhone option that builds a one-page summary for appointments, but your doctor interprets it.

Sources

  1. Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;8:CD000543. doi:10.1002/14651858.CD000543.pub5
  2. Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;8:CD000544. doi:10.1002/14651858.CD000544.pub5
  3. Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK; AGA Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156(3):748-64. doi:10.1053/j.gastro.2018.12.009
  4. Guideline Central, with the American College of Gastroenterology. Updated 2025 ACG guidelines for ulcerative colitis in adults: summary of recommendations and key concepts. https://www.guidelinecentral.com/guideline/13311/
  5. Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG clinical guideline update: ulcerative colitis in adults. Am J Gastroenterol. 2025;120(6):1187-224. doi:10.14309/ajg.0000000000003463
  6. Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 2018;3(11):742-53. doi:10.1016/S2468-1253(18)30231-0
  7. Ford AC, Khan KJ, Achkar JP, Moayyedi P. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(2):167-76. doi:10.1038/ajg.2011.410
  8. Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(1):CD004115. doi:10.1002/14651858.CD004115.pub2
  9. Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;11:CD004118. doi:10.1002/14651858.CD004118.pub2
  10. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100(11):2478-85. doi:10.1111/j.1572-0241.2005.00248.x
  11. Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing, ASCEND I and II combined analysis. Aliment Pharmacol Ther. 2011;33(6):672-8. doi:10.1111/j.1365-2036.2010.04575.x
  12. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96(10):2929-33. doi:10.1111/j.1572-0241.2001.04683.x
  13. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114(1):39-43. doi:10.1016/s0002-9343(02)01383-9
  14. Kane S, Holderman W, Jacques P, Miodek T. Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Prefer Adherence. 2008;2:253-8. doi:10.2147/ppa.s3698
  15. Jairath V, Khanna R, Zou GY, Stitt L, Mosli M, Vandervoort MK, et al. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther. 2015;42(10):1200-10. doi:10.1111/apt.13408
  16. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD). Gastroenterology. 2021;160(5):1570-83. doi:10.1053/j.gastro.2020.12.031
  17. Singh S, Ananthakrishnan AN, Nguyen NH, Cohen BL, Velayos FS, Weiss JM, et al. AGA clinical practice guideline on the role of biomarkers for the management of ulcerative colitis. Gastroenterology. 2023;164(3):344-72. doi:10.1053/j.gastro.2022.12.007
  18. US National Library of Medicine. DailyMed: LIALDA (mesalamine) delayed-release tablets prescribing information, set id 3098a080-be86-4265-9818-7fc4beab77b7. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3098a080-be86-4265-9818-7fc4beab77b7
  19. Moss JG, Parry CM, Holt RCL, McWilliam SJ. 5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review. Eur J Med Res. 2022;27(1):61. doi:10.1186/s40001-022-00687-y

Clairop is a general wellness app for people living with a diagnosed digestive condition. It does not replace professional medical care, diagnosis, or treatment. Always follow your healthcare provider's advice.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Apps for this, ranked

Free tools